Nephrotic syndrome - Pipeline Insight, 2024

This “Nephrotic syndrome - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Nephrotic syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Nephrotic syndrome Understanding

Nephrotic syndrome: Overview

Nephrotic syndrome is a group of symptoms that show your kidneys are not working as well as they should. These symptoms include too much protein in your urine, not enough protein in your blood, too much fat or cholesterol in your blood, and swelling. Anyone can get nephrotic syndrome but it is slightly more common in men than in women. In children, it happens most often between the ages of 2 and 6. The most common primary cause of nephrotic syndrome in adults is a disease called focal segmental glomerulosclerosis (FSGS). The only way to know for sure whether you have FSGS is to get a kidney biopsy. Even when treated, most people with FSGS will eventually develop kidney failure and will need to start dialysis or have a kidney transplant to live. After transplant, there is still a chance that FSGS will return and you may lose your new kidney.

Nephrotic syndrome - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nephrotic syndrome pipeline landscape is provided which includes the disease overview and Nephrotic syndrome treatment guidelines. The assessment part of the report embraces, in depth Nephrotic syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nephrotic syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nephrotic syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Nephrotic syndrome.

Nephrotic syndrome Emerging Drugs Chapters

This segment of the Nephrotic syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nephrotic syndrome Emerging Drugs

Belimumab: Glaxo SmithKlineBelimumab is a fully human monoclonal antibody that has been developed by GlaxoSmithKline/MedImmune. Currently, it is in Phase II stage of clinical trial evaluation to treat Nephroticsyndrome.

Nephrotic syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Nephrotic syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nephrotic syndrome

There are approx. 3+ key companies which are developing the therapies for Nephrotic syndrome. The companies which have their Nephrotic syndrome drug candidates in the most advanced stage, i.e. phase II include, GlaxoSmithKline.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Nephrotic syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nephrotic syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nephrotic syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nephrotic syndrome drugs.

Nephrotic syndrome Report Insights

• Nephrotic syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Nephrotic syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Nephrotic syndrome drugs?
• How many Nephrotic syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nephrotic syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nephrotic syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Nephrotic syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GlaxoSmithKline
• Goldfinch Bio, Inc.
• Travere Therapeutics, Inc.
• Aurinia Pharmaceuticals
• Bristol-Myers Squibb
• ChemoCentryx
• SynAct Pharma AB

Key Products

• Belimumab
• GFB-887
• RE-021
• Voclosporin
• Abatacept
• AP1189

This product will be delivered within 2 business days.